Passage Bio ( (PASG) ) has issued an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Passage Bio, a genetic medicines company, reported significant progress in their PBFT02 gene therapy trials for FTD-GRN, revealing promising interim data that shows potential as a leading progranulin-raising therapy. With patient enrollment on track and robust preclinical data presented at key scientific conferences, the company is poised to achieve critical milestones, supported by a strong financial position ensuring operations until mid-2026. This progress underscores Passage Bio’s commitment to advancing treatments for neurodegenerative diseases.
For an in-depth examination of PASG stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue